Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded throat spray containing lidocaine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing lidocaine are listed in injection, ointment, patch, solution, cream and jelly forms. No FDA-approved lidocaine product is listed in spray form; spray products containing it are filed as over-the-counter monograph drugs and unapproved drugs.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Lidocaine is a local anesthetic that numbs nerves where it is applied, commonly compounded in topical creams, gels, ointments and mouth rinses.
Lidocaine is an amide-type local anesthetic. It blocks sodium channels in nerve cells, which stops nerves from carrying pain signals from the area where it is applied. Many manufactured lidocaine products exist. Injectable lidocaine is FDA-approved for local and regional anesthesia and for acute treatment of certain ventricular arrhythmias. The Lidoderm patch (lidocaine 5%) is FDA-approved for relief of pain associated with post-herpetic neuralgia, and over-the-counter 4% patches are sold for minor aches. Viscous oral solutions, gels and ointments are also manufactured.
A prescriber may order lidocaine compounded when a patient needs a strength or dosage form that is not manufactured, a vehicle that avoids a specific allergen or preservative, or a combination with another active ingredient. Compounded lidocaine preparations are not FDA-approved and require a prescription.
The FDA label for viscous lidocaine 2% carries a boxed warning: in children under 3 years, seizures, cardiopulmonary arrest and death have been reported when the product was not given in strict adherence to the dosing and administration recommendations. Other label warnings include methemoglobinemia, a blood disorder that reduces oxygen delivery, with higher risk in G6PD deficiency, heart or lung disease and infants under 6 months, and toxicity when too much lidocaine is absorbed through large areas, broken skin or long contact; severe liver disease adds to that risk. Do not use lidocaine if you are sensitive to amide-type local anesthetics. Tell your prescriber or pharmacist if you take antiarrhythmics, propranolol, fluvoxamine, nitrates, dapsone or sulfonamides, or use any other lidocaine product, because absorption from all sources adds up. The label advises use in pregnancy only if clearly needed; LactMed states lidocaine is not expected to cause adverse effects in breastfed infants. If you notice burning, blistering, dizziness, confusion or gray or blue skin, stop use and talk to your prescriber or pharmacist.
Lidocaine is a tertiary amine amide local anesthetic and Vaughan-Williams class Ib antiarrhythmic. It blocks voltage-gated sodium channels from the intracellular side; its pKa of 7.7 leaves a useful uncharged fraction at physiologic pH, supporting rapid onset. Hepatic metabolism (CYP1A2 and CYP3A4) yields the active metabolites MEGX and GX; elimination half-life is roughly 1.5 to 2 hours, prolonged in heart failure and hepatic impairment. Protein binding is about 60 to 80 percent, largely to alpha-1-acid glycoprotein. From the Lidoderm patch only about 3 percent of the applied dose is absorbed through intact skin; absorption rises with non-intact skin, larger areas and longer contact.
Labeled indications: injectable lidocaine for infiltration, nerve block, epidural and IV regional anesthesia and for acute ventricular arrhythmias; Lidoderm for post-herpetic neuralgia. Prescribers have ordered lidocaine off label as a chronic and postsurgical pain adjunct and for intravesical instillation in interstitial cystitis (StatPearls). Dosing, surface area and application time are per prescriber. Monitor for methemoglobinemia and systemic toxicity, and account for total lidocaine exposure from all concurrent products. Additive toxicity with class I antiarrhythmics; propranolol raises serum lidocaine; fluvoxamine inhibits CYP1A2. Lidocaine is not a controlled substance.
Wash your hands. Open your mouth, aim the nozzle toward the back of your throat and press the pump the number of times on your label. Hold the liquid in place for a few seconds, then spit it out or swallow as your label directs. Avoid eating or drinking right after. Wipe the nozzle and recap.
Throat sprays are aqueous. Under USP <795>, a preserved spray usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Spray
